Development and internal validation of a prognostic nomogram for cancer-specific survival in Ewing sarcoma: a SEER-based study
- 1Shandong Medical and Pharmaceutical University, Binzhou, China
- 2Shandong Medical and Pharmaceutical University Hospital, Binzhou, China
Abstract
Background: Ewing sarcoma is a rare and aggressive malignancy with substantial survival heterogeneity. Conventional tumor-node-metastasis (TNM) staging provides limited individualized prognostic assessment, and previous Surveillance, Epidemiology, and End Results (SEER)-based nomograms have rarely reported optimism-corrected performance or clinical utility. This study aimed to develop and internally validate a prognostic nomogram for cancer-specific survival (CSS) in patients with Ewing sarcoma.
Methods: Using the SEER database, 720 patients with pathologically confirmed Ewing sarcoma diagnosed between 2004 and 2015 were identified. Candidate predictors were selected using least absolute shrinkage and selection operator (LASSO) regression and incorporated into a multivariable Cox proportional hazards model. Model performance was assessed using Harrell’s C-index, time-dependent area under the curve (AUC), calibration, and decision curve analysis. Internal validation was performed with 1,000 bootstrap resamples to estimate optimism-corrected performance. Multiple imputation by chained equations was used for sensitivity analysis.
Results: Among 720 patients, 258 CSS events occurred during a mean follow-up of 89.3 months. The final model included age, sex, race, primary tumor site, T stage, N stage, M stage, surgery, radiation, and chemotherapy. The apparent C-index was 0.736, with a bootstrap-corrected C-index of 0.721. The nomogram demonstrated good discrimination at 3, 5, and 10 years (AUCs: 0.795, 0.784, and 0.780, respectively) and acceptable calibration. Compared with TNM staging alone, the nomogram showed improved discrimination (C-index 0.680 vs. 0.736, P<0.001) and greater clinical net benefit. Sensitivity analysis using multiple imputation showed generally consistent predictor effects.
Conclusions: We developed and internally validated a nomogram for individualized CSS prediction in Ewing sarcoma. The model showed moderate discrimination and improved performance compared with TNM staging. However, external validation is required before clinical application.
Related
- Development and internal validation of a prognostic model for cancer-specific survival in elderly patients with metastatic non-small cell lung cancer: a SEER-based study
- A 2-year prognostic assessment of patients with coronary borderline lesions based on three-vessel quantitative flow ratio and the development and internal validation of a risk prediction nomogram
- Development and internal validation of a nomogram for predicting short- and long-term overall survival in patients with breast cancer liver metastasis: a SEER-based prognostic study
- Development and internal validation of a nomogram for predicting bacterial meningitis in preterm infants with late-onset sepsis
- Development and internal validation of a nomogram for predicting flexible bronchoscopy utilization in children with lobar pneumonia caused by Mycoplasma pneumoniae: a single-center retrospective cohort study
BibTeX
@article{wang2026development,
title = {{Development and internal validation of a prognostic nomogram for cancer-specific survival in Ewing sarcoma: a SEER-based study}},
author = {Shilong Wang and Long Jia},
journal = {Translational Cancer Research},
year = {2026},
month = sep,
doi = {10.21037/tcr-2026-1297},
url = {https://doi.org/10.21037/tcr-2026-1297},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Development and internal validation of a prognostic nomogram for cancer-specific survival in Ewing sarcoma: a SEER-based study
AU - Shilong Wang
AU - Long Jia
PY - 2026
DA - 2026/09/28
JO - Translational Cancer Research
DO - 10.21037/tcr-2026-1297
UR - https://doi.org/10.21037/tcr-2026-1297
AB - Background: Ewing sarcoma is a rare and aggressive malignancy with substantial survival heterogeneity. Conventional tumor-node-metastasis (TNM) staging provides limited individualized prognostic assessment, and previous Surveillance, Epidemiology, and End Results (SEER)-based nomograms have rarely reported optimism-corrected performance or clinical utility. This study aimed to develop and internally validate a prognostic nomogram for cancer-specific survival (CSS) in patients with Ewing sarcoma. Methods: Using the SEER database, 720 patients with pathologically confirmed Ewing sarcoma diagnosed between 2004 and 2015 were identified. Candidate predictors were selected using least absolute shrinkage and selection operator (LASSO) regression and incorporated into a multivariable Cox proportional hazards model. Model performance was assessed using Harrell’s C-index, time-dependent area under the curve (AUC), calibration, and decision curve analysis. Internal validation was performed with 1,000 bootstrap resamples to estimate optimism-corrected performance. Multiple imputation by chained equations was used for sensitivity analysis. Results: Among 720 patients, 258 CSS events occurred during a mean follow-up of 89.3 months. The final model included age, sex, race, primary tumor site, T stage, N stage, M stage, surgery, radiation, and chemotherapy. The apparent C-index was 0.736, with a bootstrap-corrected C-index of 0.721. The nomogram demonstrated good discrimination at 3, 5, and 10 years (AUCs: 0.795, 0.784, and 0.780, respectively) and acceptable calibration. Compared with TNM staging alone, the nomogram showed improved discrimination (C-index 0.680 vs. 0.736, P<0.001) and greater clinical net benefit. Sensitivity analysis using multiple imputation showed generally consistent predictor effects. Conclusions: We developed and internally validated a nomogram for individualized CSS prediction in Ewing sarcoma. The model showed moderate discrimination and improved performance compared with TNM staging. However, external validation is required before clinical application.
SN - 2218-676X
SN - 2219-6803
ER -